纵向循环肿瘤DNA识别非肌层浸润性膀胱癌高危进展与复发
该研究纳入52例高危非肌层浸润性膀胱癌患者,采用个体化肿瘤知情循环肿瘤DNA(ctDNA)纵向检测。33%患者可检出ctDNA,ctDNA阳性者临床分期升级(59% vs 14%,P=0.002)和病理分期升级(78% vs 8%,P=0.002)风险显著更高,且出现远处复发。ctDNA阳性反映侵袭性肿瘤生物学,可能识别不适合继续膀胱内挽救治疗的患者。
要点
- 高危NMIBC中纵向ctDNA检测可识别临床和病理分期升级及远处复发高风险亚组。
- ctDNA阳性患者常无膀胱镜或影像学对应证据,提示其反映侵袭性肿瘤生物学。
- ctDNA阳性可能帮助识别不太可能从持续膀胱内挽救治疗中获益的患者。
核心结论
- 高危NMIBC中纵向ctDNA检测可识别临床和病理分期升级及远处复发风险更高的亚组,且常无膀胱镜或影像学对应证据。
研究设计与样本
- 队列研究,纳入52例高危NMIBC患者,采用个体化肿瘤知情检测进行系列血浆ctDNA检测,部分肿瘤行肿瘤-正常全外显子测序。
主要发现
- 52例中17例(33%)可检出ctDNA,其中BCG初治者8/29(28%),BCG暴露/无反应者9/23(39%)。
- 临床分期升级发生于17例ctDNA阳性者中10例 vs 35例阴性者中5例(59% vs 14%,P=0.002)。
- 21例膀胱切除术患者中,病理分期升级发生于9例ctDNA阳性者中7例 vs 12例阴性者中1例(78% vs 8%,P=0.002)。
- 远处复发发生于3/17(18%)ctDNA阳性患者,ctDNA阴性患者中无远处复发。
- TP53改变在ctDNA阳性肿瘤中富集,FGFR3改变在ctDNA阴性肿瘤中更常见。
临床怎么用
- 纵向ctDNA检测可作为高危NMIBC潜在风险分层工具,辅助识别可能不适合继续膀胱内挽救治疗的患者。
- ctDNA阳性且无膀胱镜或影像学证据时,应警惕分期升级和远处复发风险,考虑更积极评估或治疗策略。
局限性
- 队列样本量小且随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether longitudinal tumour-informed circulating tumour DNA (ctDNA) testing identifies patients at increased risk of upstaging and recurrence in high-risk non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A cohort of 52 patients with high-risk NMIBC underwent serial plasma ctDNA testing using a personalised tumour-informed assay. The ctDNA was obtained at initial presentation and at approximately 3-month surveillance intervals during appropriate routine clinical NMIBC therapy and follow-up. A subset of tumours underwent tumour-normal whole-exome sequencing to evaluate genomic alterations associated with ctDNA detection and clinical progression. RESULTS: Circulating tumour DNA was detectable in 17 of 52 patients (33%), including eight of 29 who were Bacillus Calmette-Guérin (BCG)-naïve (28%) and nine of 23 who were BCG-exposed/BCG-unresponsive patients (39%). Most patients received intravesical therapy, including BCG or salvage intravesical chemotherapy, and a subset underwent radical cystectomy. Clinical upstaging occurred in 10 of 17 ctDNA-positive patients vs five of 35 ctDNA-negative patients (59% vs 14%, P = 0.002). Among the 21 patients undergoing cystectomy, pathological upstaging occurred in seven of nine ctDNA-positive patients and one of 12 ctDNA-negative patients (78% vs 8%, P = 0.002). Distant recurrence occurred in three of 17 (18%) ctDNA-positive patients and in none of ctDNA-negative patients. TP53 alterations were enriched in ctDNA-positive tumours, whereas fibroblast growth factor receptor (FGFR3) alterations were more frequent in ctDNA-negative tumours. Limitations include the small cohort and limited follow-up. CONCLUSION: Longitudinal ctDNA testing in high-risk NMIBC identifies a subgroup with higher risk of clinical and pathological upstaging and distant recurrence, often without corresponding cystoscopic or radiographic evidence. ctDNA-positivity reflects aggressive tumour biology and may help identify patients unlikely to benefit from continued intravesical salvage therapy. These findings support further evaluation of ctDNA as a potential risk stratification tool and motivate prospective studies of ctDNA-guided management.
引用
- Aydogdu C, Wang B, McSweeney ST, et al. Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer. BJU Int. 2026. PMID: 42389921. doi:10.1111/bju.70376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。